Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Should You Buy?

Key Points

• Archimed agreed to take Esperion private for up to $1.1 billion, offering $3.16 per share in cash plus up to $100M in milestones, which drove the stock to gap up from $2.00 to an opening price of $3.13 and heavy trading volume.
• Unusually heavy call‑option buying (about 7,568 calls, ~212% above average) points to speculative or institutional bets on further upside or volatility around the deal.
• Two investor‑rights firms have launched investigations into whether shareholders are receiving a fair price and HC Wainwright downgraded the stock, creating potential litigation and valuation/execution risks for the transaction.

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $2.00, but opened at $3.13. Esperion Therapeutics shares last traded at $3.1150, with a volume of 91,952,489 shares changing hands.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Archimed agreed to take Esperion private for up to $1.1 billion, offering $3.16 per share in cash plus up to $100M in milestone payments — a clear near-term liquidity event that drove the stock higher. Archimed to take Esperion private in $1.1 billion deal Esperion to be Acquired by ARCHIMED
• Positive Sentiment: Unusually heavy call-option buying (roughly 7,568 calls, ≈212% above average) suggests speculative or institutional interest betting on further upside or volatility around the deal. (No article link provided.)
• Neutral Sentiment: Trading in ESPR was temporarily halted before the market opened for a “news pending” announcement, consistent with the company/market processing the acquisition disclosure and analysts’ reactions.
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and Ademi LLP) have launched investigations into whether Esperion shareholders are receiving a fair price in the sale, which could lead to litigation or a challenge to deal terms and add execution risk. Halper Sadeh investigation Ademi LLP investigation
• Negative Sentiment: HC Wainwright downgraded ESPR from “buy” to “neutral,” increasing analyst skepticism about deal valuation or future upside for remaining optionality; downgrades can weigh on post‑announcement trading. (Downgrade reported in market feed.)

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. HC Wainwright cut shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Citizens Jmp increased their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a "market outperform" rating in a report on Friday, March 13th. Finally, Needham & Company LLC raised their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $8.75.

Esperion Therapeutics Stock Up 55.8%

The firm has a market cap of $801.80 million, a P/E ratio of -18.32, a PEG ratio of 1.55 and a beta of 1.17. The firm's fifty day moving average is $2.55 and its two-hundred day moving average is $3.07.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to the consensus estimate of $165.12 million. As a group, sell-side analysts forecast that Esperion Therapeutics, Inc. will post 0.05 EPS for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd boosted its position in shares of Esperion Therapeutics by 23.5% during the fourth quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 2,890 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Esperion Therapeutics by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company's stock worth $144,000 after acquiring an additional 3,614 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 3,822 shares during the last quarter. Eaton Financial Holdings Company LLC lifted its position in Esperion Therapeutics by 9.4% during the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company's stock valued at $172,000 after purchasing an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Esperion Therapeutics by 18.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 4,422 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.